Jefferies Group’s Acceleron Pharma XLRN Stock Holding History

Jefferies Group’s Portfolio XLRN Stock Details XLRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-2,519	Closed	-$316K	–	2183
2021 Q2	$316K	Buy	2,519 +122	+5%	+$15.4K	﹤0.01%	1297
2021 Q1	$325K	Buy	+2,397	New	+$310K	﹤0.01%	1220
2020 Q3	–	Sell	-2,250	Closed	-$214	–	1640
2020 Q2	$214	Buy	2,250 +45	+2%	+$4.34K	﹤0.01%	1066
2020 Q1	$198K	Sell	2,205 -2,676	-55%	-$208K	﹤0.01%	1680
2019 Q4	$259K	Sell	4,881 -2,756	-36%	-$126K	﹤0.01%	2128
2019 Q3	$302K	Buy	+7,637	New	+$331K	﹤0.01%	2181
2015 Q3	–	Sell	-88	Closed	-$3K	–	3305
2015 Q2	$3K	Sell	88 -8,925	-99%	-$288K	﹤0.01%	3112
2015 Q1	$343K	Buy	+9,013	New	+$358K	﹤0.01%	1543

Other funds holding XLRN

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

DGM

Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BAMCO Inc New York $33.1B AUM 11.16% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Jefferies Group's XLRN Position: Q3 2021 in Review

Jefferies Group sold out of Acceleron Pharma (XLRN) in Q3 2021, closing a stake of 2,519 shares — an estimated $316K sold.

Jefferies Group first reported a position in XLRN in Q1 2015 and held it in 8 quarters. The position peaked at $343K in Q1 2015. 330 funds tracked by Wall St. Rank hold XLRN as of Q3 2021.

Jefferies Group reported no remaining Acceleron Pharma position as of Q3 2021 after selling out during the quarter.
Jefferies Group sold 2,519 Acceleron Pharma shares in Q3 2021, an estimated $316K.
Jefferies Group first reported a position in Acceleron Pharma in Q1 2015 and held it in 8 quarters.
Jefferies Group's Acceleron Pharma position peaked at $343K in Q1 2015.
330 funds tracked by Wall St. Rank held Acceleron Pharma as of Q3 2021.

Based on Jefferies Group's 13F filing for Q3 2021, filed 15 Nov 2021.